PICS enters June with a complicated scorecard: a blowout Q1 result, insider buying at the bottom, and an analyst base that still rates the stock Outperform — yet keeps marking down its targets.
The Q1 print is the place to start. PicS N.V. reported adjusted EPS of $0.25 and revenue of $667M for the first quarter, up from $392M a year ago — a 70% year-on-year sales jump that landed cleanly above expectations. The stock gained about 1% Tuesday and closed at $11.17, adding a modest 0.3% for the week. That muted reaction to a strong beat is itself a signal: the Street appears to be discounting near-term execution against a March earnings event that sent the stock down 27% in a single day. Investors are watching closely to see whether the revenue acceleration can hold.
The positioning picture is less alarming than it first appears. Short interest climbed 31% over the past week to roughly 846K shares, or about 2.5% of the free float — elevated by absolute count but not a crowded short in relative terms. The borrow market is loose: availability is running at 216%, meaning there are more than two shares available to lend for every share already borrowed. That is well above the 52-week trough of 83%. Cost to borrow has also eased sharply, dropping from a month-ago level near 3.5% to just over 2%, its lowest since listing. With ample supply and falling carry costs, the short base is opportunistic rather than structural — there's no evidence of a coordinated squeeze setup. The ORTEX short score has drifted down from 52 at end-May to 45.7 today, reinforcing that the aggregate bearish signal is fading, not building.
Analyst direction is unambiguously bullish in rating, but the target price trajectory is a slow bleed. RBC Capital's Daniel Perlin — who initiated coverage in February at $20 — trimmed his target today to $18 while keeping his Outperform rating, the third downward revision in two months. Mizuho and Citi, both of whom also initiated in February at $30 and $28 respectively, have since revised lower as well. The consensus mean sits near $107 on legacy data that appears to reflect a different share class or currency base and should be disregarded; the actionable analyst targets cluster between $18 and $21. That still implies 60-90% upside to the current $11.17 price — a gap that flags either a structurally mispriced stock or persistent analyst optimism in the face of a difficult re-rating. No analyst has cut the stock to Neutral or below.
Valuation provides some support for the bull case. The stock trades at a P/E of 5.1x and a price-to-book below 1x, levels that suggest the market is pricing in continued pressure rather than the revenue growth the Q1 result demonstrated. The EV/EBITDA multiple of 1.3x is extremely compressed. Those numbers have drifted modestly lower over the past 30 days but recovered from deeper troughs earlier in the quarter. The ORTEX combined score of 45.5 is middling — neither screaming value nor momentum — but the recent valuation note from ORTEX's own scoring system flagged a meaningful improvement in the valuation pillar over the past two months.
Insider activity adds a constructive layer to the picture. In March, a director bought $1.18M worth of shares at $11.80, and the CEO followed with a $1M purchase at $11.52 — both near current prices. The Chief Strategy Officer has also added to his position in two separate transactions. Net insider buying totalled approximately $2.3M over the past 90 days, all on the buy side. That cluster of management buying below current market price is the clearest signal of internal confidence in the stock.
The next scheduled earnings event is June 26. Given the March result's 27% single-day drop and the June 2 Q1 beat, the shape of the next print — and specifically whether the revenue growth rate sustains or decelerates — will define whether the current analyst consensus is vindicated or further revised lower.
See the live data behind this article on ORTEX.
Open PICS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
